- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05910489
Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect
New Tools for the Detection of Micro and NanoPLastics (MNPLs) in Greenhouse Workers as a Population Highly Exposed to Plastics: Effect on Different Biomarkers of Genotoxic Effect
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The exponential increase in the production/use of plastic translates into a parallel increase of environmental plastic waste that is continuously degraded into MNPLs. Information on the MNPLs' effects on human health is still preliminary and, furthermore, the limitations in current methodologies prevent accurate exposure/risk assessment.
This observational study will obtain body samples of greenhouse workers and from a control group. That would allow optimizing specific biomarkers of human MNPLs exposure and the characterization of biomarkers of early effect that allows an association among the exposure to MNPLs and effects on human health.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ricard Marcos
- Phone Number: +34 93 586 20 52
- Email: ricard.marcos@uab.cat
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria of workers exposed to plastic residues:
- Working in an operating greenhouse for a period of 1 month or more
- Age over 18 years old
- Absence of chronic pathology including neoplasia
- Absence of infectious disease at the date of sample collection and for a period of more than 2 weeks
- Spanish residence
Inclusion Criteria of controls :
- Age over 18 years old. Matched by age, gender, and lifestyle to the exposed group.
- Absence of chronic pathology including neoplasia
- Absence of infectious disease at the date of sample collection and for a period of more than 2 weeks
- Spanish residence
Exclusion Criteria of workers exposed to plastic residues:
- Participation in another clinical study
- Pregnancy
- Unsigned informed consent
Exclusion Criteria of controls:
- Participation in another clinical study
- Pregnancy
- Unsigned informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Control
Biomonitoring studies to detect MNPLs in biological samples and study of health effects. Determination of MNPLs levels, genotoxic damage, and immunological effects |
Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
|
|
Greenhouse workers
Biomonitoring studies to detect MNPLs in biological samples and study of health effects. Determination of MNPLs levels, genotoxic damage, and immunological effects |
Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biomonitoring study to detect the presence of MNPLs in body fluids
Time Frame: Up to 1 year
|
Blood, buccal cells, exhalate breath condensate, feaces and urine will be collected from donors to check for the presence of micro and nanoplastics and/or derivatives
|
Up to 1 year
|
|
Genotoxicity effects of exposure to MNPLs
Time Frame: Up to 1 year
|
Blood and buccal cells will be collected from donors to check for the presence genotoxic permanent damage, assessed by the micronucleus assay
|
Up to 1 year
|
|
Genotoxicity effects of exposure to MNPLs
Time Frame: up to 1 year
|
Blood will be collected from donors to check for the presence genotoxic non-permanent damage, assessed by the comet assay
|
up to 1 year
|
|
Study of the effects of MNPLs on immune system
Time Frame: Up to 1 year
|
Blood will be collected from donors to check if the presence of micro and nanoplastics have an effect on th function of the immune system (signalling and activation) in vivo and in high-risk individuals
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surrogate biomarkers after MNPLs exposure
Time Frame: Up to 1 year
|
If it is possible to correlate the presence of micro and nanoplastics with the presence of plastic derivatives in body fluids, as blood or urine, this will facilitate the detection of plastic, because tecniques to detect surrogate biomarkers as e.g.
plasticizers or antioxidants are cheaper and most use than the tecnology to detect MNPLs.
For that different analytical tecniques will be used.
|
Up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pablo Pelegrín, Instituto Murciano de Investigación Biosanitaria (IMIB)
- Study Chair: Juan Bernardo Cabezuelo, Hospital Clínico Universitario Virgen de Arrixaca (Murcia)
- Study Chair: Laura Martínez, Hospital Clínico Universitario Virgen de Arrixaca (Murcia)
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Center for Research and Innovation Viña Concha...Universidad Católica del MauleNot yet recruitingInflammaging | Antioxidant Status, Inflammation | Inflammation Biomarkers | Antioxidant Capabilities | Cardiometabolic Health IndicatorsChile
-
University of NebraskaNot yet recruiting
-
Ahmad ElheenyActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
Clinical Trials on Biomonitoring of MNPLs in biological samples of greenhouse workers and controls
-
Ricard MarcosHospital Universitario Virgen de la Arrixaca; Instituto Murciano de Investigación...RecruitingChronic Kidney Diseases | Microplastics | Nanoplastics | Genotoxic DamageSpain
-
Thomas Jefferson UniversityActive, not recruitingHealthy | Anxiety | Distress, Emotional | Effects of VibrationUnited States
-
Rigshospitalet, DenmarkRecruitingPolyneuropathies | Diabetic Polyneuropathy | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | POEMS Syndrome | Multifocal Motor Neuropathy | Charcot-Marie-Tooth | hATTR Amyloidosis | Vasculitic Neuropathy | Idiopathic NeuropathyDenmark
-
Université Catholique de LouvainEuropean Society for Clinical Nutrition and MetabolismCompletedAcute Myeloid Leukemia | CachexiaBelgium
-
MaaT PharmaCompletedBone and Joint InfectionFrance
-
Centre Hospitalier Régional d'OrléansTerminatedCOVID-19 | SARS CoV 2 InfectionFrance
-
University Hospital, BordeauxCompletedImmune Thrombocytopenic Purpura | Thrombopenia | Autoimmune Thrombocytopenia
-
Vanderbilt University Medical CenterAmerican Heart AssociationRecruitingLong COVID | SARS CoV 2 Infection | Post-acute COVID-19 Syndrome | Postural Tachycardia Syndrome (POTS)United States
-
University Hospital, ToulouseActive, not recruitingPancreatic AdenocarcinomaFrance
-
University Hospital, ToulouseRecruitingNeoplasms | Adenocarcinoma | CarcinomaFrance